Polymorphisms in the interleukin-10 gene cluster are possibly involved in the increased risk for major depressive disorder by Traks, Tanel et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
Polymorphisms in the interleukin-10 gene cluster are possibly 
involved in the increased risk for major depressive disorder
Tanel Traks*1,2, Kati Koido1,2, Triin Eller2,3, Eduard Maron3,4,5, Külli Kingo2,6, 
Veiko Vasar2,3, Eero Vasar1,2 and Sulev Kõks1,2,7
Address: 1Department of Physiology, University of Tartu, Ravila 19, 50411 Tartu, Estonia, 2Centre of Molecular and Clinical Medicine, University 
of Tartu, Tartu, Estonia, 3Department of Psychiatry, University of Tartu, Tartu, Estonia, 4Research Department of Mental Health, The North 
Estonian Regional Hospital, Psychiatry Clinic, Tallinn, Estonia, 5Estonian Genome Foundation, University of Tartu, Tartu, Estonia, 6Department 
of Dermatology and Venerology, University of Tartu, Tartu, Estonia and 7Institute of Veterinary Medicine and Animal Sciences, Estonian University 
of Life Sciences, Tartu, Estonia
Email: Tanel Traks* - tanel.traks@ut.ee; Kati Koido - kati.koido@ut.ee; Triin Eller - triin.eller@kliinikum.ee; 
Eduard Maron - eduard.maron@kliinikum.ee; Külli Kingo - kylli.kingo@kliinikum.ee; Veiko Vasar - veiko.vasar@kliinikum.ee; 
Eero Vasar - eero.vasar@ut.ee; Sulev Kõks - sulev.koks@ut.ee
* Corresponding author    
Abstract
Background:  Innate immune inflammatory response is suggested to have a role in the
pathogenesis of major depressive disorder (MDD). Interleukin (IL)-10 family cytokines IL-10, IL-19,
IL-20, and IL-24 are all implicated in the inflammatory processes and polymorphisms in respective
genes have been associated with various immunopathological conditions. This study was carried
out to investigate whether single-nucleotide polymorphisms (SNPs) in these genes are also
associated with MDD.
Methods: Case-control association study was performed with seven SNPs from the IL10 gene
cluster. 153 patients with MDD and 277 healthy control individuals were recruited.
Results:  None of the selected SNPs were individually associated with MDD. The linkage
disequilibrium (LD) analysis indicated the existence of two recombination sites in the IL10 gene
cluster, thus confirming the formerly established LD pattern of this genomic region. This also
created two haplotype blocks, both consisting of three SNPs. Additionally, the haplotype analysis
detected a significantly higher frequency of block 2 (IL20 and IL24 genes) haplotype TGC in the
patients group compared to healthy control individuals (P = 0.0097).
Conclusion: Our study established increased risk for MDD related to the IL20 and IL24 haplotype
and suggests that cytokines may contribute to the pathogenesis of MDD. Since none of the block
2 SNPs were individually associated with MDD, it is possible that other polymorphisms linked to
them contribute to the disease susceptibility. Future studies are needed to confirm the results and
to find the possible functional explanation.
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Background
Major depression (MD or major depressive disorder,
MDD) is a complex disease that not only affects the lives
of the patients but also their family members and is one
of the major causes of disability worldwide, ranking 4th
according to a recent survey of global burden of disease
and estimated to become 2nd by 2030 [1]. To date, the
most popular explanation of the cause has been the
monoamine hypothesis which only encompasses a part of
the disturbances producing the disease. Hence, many new
theories and prospects for pharmacotherapy are currently
being developed [2]. Among these, considerable effort has
been made to elucidate the role of the innate immune
inflammatory response in depression with elevated pro-
inflammatory cytokines influencing neurotransmitter
metabolism, neuroendocrine function, synaptic plasticity
and information processing [3].
Interleukin (IL)-10 and it's recently discovered paralogs
IL-19, IL-20, and IL-24 are all implicated in the inflamma-
tory processes and act on the Th1/Th2 cytokine balance
[4]. All of their genes are located in the IL10 gene cluster
in a 200 kb region of chromosome 1 within the locus q31-
32. In accordance with the proposed role of these
cytokines in various inflammatory diseases, the polymor-
phisms in respective genes have also been associated with
many immunopathological conditions, especially psoria-
sis [5-7]. In addition, while elevated pro-inflammatory
cytokines such as IL-1, IL-6 and TNF-α (tumor necrosis
factor α) have been associated with MDD, IL-10 as a coun-
teractive anti-inflammatory cytokine has been studied
directly in reference to MDD. Results describing the rela-
tionship between MDD and IL-10 production have so far
been inconsistent, showing increased [8,9], unchanged
[10] or decreased [11] levels of IL-10 in depressed
patients, and also differentiating between depressive sub-
types [12]. It has been suggested that in case of the
increased IL-10 it may indicate a compensatory anti-
inflammatory response against generalized inflammatory
state in MDD [13]. Furthermore, antidepressants have
been shown to stimulate the production of IL-10 along
with the reduction of the general pro-inflammatory/anti-
inflammatory cytokine ratio [14]. In respect to neuro-
transmitter metabolism, IL-10 inhibits the nearly ubiqui-
tously expressed indoleamine 2,3-dioxygenase (IDO), an
enzyme responsible for directing tryptophan degradation
along the kynurenine pathway [15], thus possibly increas-
ing the availability of tryptophan for serotonin synthesis
and decreasing the levels of neurotoxic N-methyl-D-aspar-
tate (NMDA) receptor agonist quinolinic acid and NMDA
antagonist kynurenic acid [16]. Finally, astrocytes which
release IL-10 in the central nervous system and are espe-
cially sensitive to the apoptotic effects of quinolinic acid,
have been observed to be reduced in MDD [16,17].
Considering the active role of IL10 cluster cytokines in
inflammatory processes and the impaired immune func-
tion in MDD, and also the specific evidences linking IL-10
to MDD, the present study was aimed to investigate the
possible association between genetic variations in these
genes and MDD. We selected seven SNPs from the IL10
gene cluster to determine their individual and haplotype
associations with MDD. It should also be noted that the
genome-wide linkage analysis has identified the chromo-
some 1q31-32 region that contains the IL10 gene cluster
as one of the susceptibility loci to bipolar disorder, known
for its high comorbidity with MDD [18].
Methods
Study sample
Unrelated patients (n = 153; 38 males; 115 females; mean
age ± SD: 40.5 ± 13.4 yr) with MDD were recruited in the
study along with healthy control individuals (n = 277; 70
males; 206 females; mean age ± SD: 39.4 ± 14.0 yr) from
the Estonian population. Diagnoses of patients were sub-
stantiated by psychiatric interview and verified by Mini
International Neuropsychiatric Interview (M.I.N.I. 5.0.0)
based on DSM-IV [19]. The case group consisted of
patients with only MDD and patients with MDD and
comorbid anxiety disorders (panic disorder, generalized
anxiety disorder, obsessive compulsive disorder, social
fobia). Controls were evaluated using M.I.N.I. to exclude
those with psychiatric morbidity, and with a family his-
tory interview to exclude those with a known history of
major psychiatric disorders in first-degree relatives.
Patients were recruited among consecutive outpatients
and in-patients at the Clinic of Psychiatry of Tartu Univer-
sity Hospital and controls were recruited by newspaper
advertisement in Tartu, Estonia. The study was conducted
in accordance with the principles of the Declaration of
Helsinki. The Ethics Review Committee on Human
Research of the University of Tartu approved the study
protocol. Each subject provided written informed con-
sent.
Marker selection and genotyping
In our previous study, we identified two haplotype blocks
within the IL10 gene cluster encompassing thirteen SNPs
from IL19, IL20, and IL24 genes [6]. Among these, six tag
SNPs (three from both blocks) were selected for this study
using the Haploview Tagger program [20]. The selected
SNPs of block 1 were rs2243188 and rs2243193 of IL19
(intron 6, 3' UTR) and rs2981572 of IL20 (5' near gene)
and SNPs of block 2 were rs1518108 of IL20 (3' UTR),
rs1150253 and rs1150258 of IL24  (intron 2, exon 5).
Additionally, we included rs1800872 of IL10 (5' UTR)
that lies within the putative STAT 3 binding site and has
been associated with IL-10 expression [21,22]. All selected
SNPs had a minor allele frequency above 20% and were
separated by more than 1000 bp.BMC Medical Genetics 2008, 9:111 http://www.biomedcentral.com/1471-2350/9/111
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Genomic DNA was extracted from the whole blood and
the SNPs rs2243193, rs2981572, and rs1150253 were
analyzed by the tetra-primer ARMS-PCR method as
described previously [6,23,24]. For the SNPs rs1800872,
rs2243188, rs1518108, and rs1150258 the Applied Bio-
systems (Foster City, California) SNPlex™ assay was used
[25]. This method is based on the oligonucleotide liga-
tion/polymerase chain reaction assay (OLA/PCR) using
allele-specific ZipCode™ probes and adaptors followed by
hybridization of fluorescently labelled ZipChute™ probes
that allow the detection of genotypes by capillary electro-
phoresis. The probes were detected with an Applied Bio-
systems 3730 DNA Analyzer, and data interpretation was
performed with the Applied Biosystems Genemapper v4.0
software.
Statistical analyses
Single marker association analysis and multimarker hap-
lotype association tests between groups of patients and
controls and Hardy-Weinberg equilibrium calculations in
both groups were performed using the Haploview v4.0
software [20]. Analysis of genotype frequencies was per-
formed using the web version of Genepop [26]. The Solid
Spine of linkage disequilibrium (LD) method was used to
define the haplotype blocks and the resulting blocks were
used in the haplotype association test. The extent of dise-
quilibrium was demonstrated by the standardized D'
characteristic that was multiplied by 100 in the LD illus-
tration generated in Haploview. One thousand permuta-
tions were used to correct P-values for multiple testing
error in haplotype analysis.
Results
Seven SNPs of the genomic region of IL10, IL19, IL20, and
IL24 genes (IL10 cluster) were analyzed in 153 Estonian
patients with MDD and 277 healthy control subjects.
Genotype frequencies of these polymorphisms did not
deviate significantly from the Hardy-Weinberg equilib-
rium in neither of the groups. Comparing genotype and
allele frequencies between MDD patients and controls,
none of the analyzed seven SNPs showed statistically sig-
nificant association with susceptibility to MDD (Table 1).
Haplotype analysis of the IL10, IL19, IL20, and IL24 genes
was performed according to the pairwise linkage disequi-
librium pattern observed within each of these genes (cases
+ controls, n = 429). The LD analysis indicated the exist-
ence of two recombination sites in the IL10 gene cluster,
the first between rs1800872 of IL10 and rs2243188 of
IL19 (|D'| = 0.25) and the second between rs2982572 and
rs1518108 of IL20 (|D'| = 0.03; Figure 1). This also created
two haplotype blocks, one containing rs2243188,
rs2243193, and rs2981572 (the first two SNPs from IL19
and the third SNP from IL20 gene; |D'| 0.94–0.96) and
the other containing rs1518108, rs1150253, and
rs1150258 (the first SNP from IL20 and the rest from IL24
gene; |D'| 0.91–0.99; Figure 1). Four common haplotypes
with an estimated frequency ≥ 1% were identified in both
blocks, together comprising 98.6% and 99.1% of all hap-
lotypes in block 1 and block 2, respectively. Additionally,
the haplotype analysis provided one haplotype signifi-
cantly associated with increased disease susceptibility.
Namely, the block 2 haplotype TGC frequency was signif-
icantly higher in patients with MDD compared to the con-
trol group (P = 0.0097; OR 3.45; 95% CI 1.28–9.32; Table
2) and the result remained statistically significant after
permutations (Padj = 0.042; Table 2). However, the overall
frequency of this haplotype was only 2.1% in the pooled
group of patients and controls.
Table 1: Genotype and allele frequencies of SNPs from the IL10 gene cluster in MDD patients (n = 153) and control individuals (n = 
277)
Alleles Genotypes Alleles
SNP ID 1/2* Groups 11 12 22 P-value 1 2 P-value
rs1800872 C/A Controls 51.0 41.3 7.7 0.5460 71.6 28.4 0.5238
Patients 53.2 41.0 5.8 73.7 26.3
rs2243188 C/A Controls 65.8 30.7 3.5 0.1790 81.1 18.9 0.1820
Patients 57.1 40.0 2.9 77.1 22.9
rs2243193 G/A Controls 62.8 33.1 4.1 0.4803 79.3 20.7 0.4636
Patients 59.2 35.9 4.9 77.1 22.9
rs2981572 T/G Controls 48.4 42.9 8.7 0.6789 69.9 30.1 0.6406
Patients 46.4 43.6 10.0 68.2 31.8
rs1518108 C/T Controls 27.5 56.6 15.9 0.8755 55.8 44.2 0.8251
Patients 29.5 51.1 19.4 55.0 45.0
rs1150253 G/A Controls 27.1 55.2 17.7 0.8855 54.7 45.3 0.8657
Patients 31.9 46.8 21.3 55.3 44.7
rs1150258 T/C Controls 27.0 56.4 16.6 0.8741 55.2 44.8 0.8227
Patients 29.9 48.9 21.2 54.4 45.6
* 1 represents the major allele, 2 represents the minor alleleBMC Medical Genetics 2008, 9:111 http://www.biomedcentral.com/1471-2350/9/111
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Discussion
Numerous studies have established statistical associations
of the IL10  gene cluster polymorphisms with various
inflammatory diseases [5-7] and the innate immune
inflammatory response is suggested to have a role in the
etiology of MDD [3]. Deriving from that, the present
study was intended to determine the associations between
seven selected SNPs from the aforementioned genomic
region and MDD.
The results indicated that none of the SNPs were individ-
ually associated with MDD. On the part of the IL10 gene,
this was in line with a previous report also finding no
association between the IL10 gene and MDD, analyzing a
promoter polymorphism at position -819 in that case
[27]. Other studies investigating the association between
cytokine gene polymorphisms and MDD have lead to
diverse results. No significant associations were found
between the polymorphisms from IL1B [28], IL6 [29] and
TNFB [30] genes and MDD, although there was a trend for
patients who were homozygous for the -511T allele of the
IL1B gene to have less severity depressive symptoms and
more favourable fluoxetine therapeutic response than -
511C carriers [28]. However, polymorphisms from TNFA
[31] and CCL2  [32] genes were associated with MDD.
Also, single polymorphisms and seven haplotypes from
inflammation-related genes involved in T-cell functioning
PSMB4 and TBX21 were associated with MDD susceptibil-
ity [33].
The LD analysis indicated the existence of two recombina-
tion sites in the IL10  gene cluster, the first between
rs1800872 and rs2243188 (|D'| = 0.25) and the second
between rs2982572 and rs1518108 (|D'| = 0.03), thus
confirming the formerly established LD pattern of this
genomic region [6,34]. The resulting two haplotype
blocks consisted of rs2243188, rs2243193, and
rs2982572 (|D'| 0.94–0.96); and rs1518108, rs1150253,
and rs1150258 (|D'| 0.91–0.99). Additionally, the haplo-
type analysis revealed that the frequency of the block 2
haplotype TGC was significantly higher among patients
compared to controls and was therefore associated with
susceptibility to MDD (P = 0.0097; OR 3.45; 95% CI
1.28–9.32). However, this result should be approached
with caution, as the overall frequency of this haplotype
was only 2.1% in the pooled group of patients and con-
trols. The block 2 contained one SNP from the IL20 gene
and two from the IL24 gene and since these SNPs weren't
individually associated with MDD, it is possible that the
polymorphisms contributing to the increased disease sus-
ceptibility are linked to them in the same haplotype block.
Considering the elevated levels of inflammatory media-
tors in MDD and the mainly pro-inflammatory nature of
IL-20 and IL-24 cytokines, these functional polymor-
phisms could affect the immunological states in the con-
text of MDD. In addition, the block 2 extends further from
the  IL24  gene in 3' direction and includes the genes
FAIM3, PIGR, and FCAMR (HapMap, genome build 35),
that could also be affected by alternative haplotypes.
Unfortunately, specific causal explanations connecting
SNPs and MDD are beyond the scope of this research and
could be established in functional studies.
Conclusion
The present study established increased risk for MDD
related to the IL20 and IL24 haplotype and suggests that
cytokines may contribute to the pathogenesis of MDD.
Since none of the block 2 SNPs were individually associ-
ated with MDD, it is possible that other polymorphisms
linked to them contribute to the disease susceptibility.
The main limitation in this case was the small sample size
that hinders the detection of small effects. Confirmative
study with increased number of the SNPs and a larger
sample is needed.
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